Oregon State University
Corvallis, Oregon, 97331, United States
Location status: Recruiting
Location contact
Emily Ho, PhD
PRINCIPAL_INVESTIGATOR
Sandra Uesugi, RN, BSN, MS
CONTACT
NCT Number: NCT06942351
The purpose of this study is to examine the impact of daily consumption of walnuts for 12 weeks on cognitive function, markers of inflammation and oxidative stress, and the gut microbiome in healthy adults age 55 years and older.
Interested in participating?
Request Info55 year and older
All sexes
Interventional
Not applicable
Corvallis, Oregon, 97331, United States
Location status: Recruiting
Emily Ho, PhD
PRINCIPAL_INVESTIGATOR
Sandra Uesugi, RN, BSN, MS
CONTACT
The investigators will determine the extent to which daily consumption of walnuts by older adults for 12 weeks influences cognitive function and whether improvements are associated with changes in the resident gut microbiota. The investigators propose that age-related cognitive decline can be mitigated by consuming walnuts, by modulating the microbiota and microbial metabolites and decreasing oxidative stress and inflammation.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daily consumption of 1.5 ounces of plain walnuts for 12 weeks
Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 1.5 ounces of plain walnuts)
Time frame: 0 and 12 weeks
Change from baseline at week 12: age adjusted standard scores (higher score reflects positive outcome)
Time frame: 0 and 12 weeks
Change from baseline at week 12: proximity (lower score reflects positive outcome)
Time frame: 0 and 12 weeks
Change from baseline at week 12: age adjusted standard scores (higher score reflects positive outcome)
Time frame: 0 and 12 weeks
Change from baseline at week 12: proximity (lower score reflects positive outcome)
Time frame: 0 and 12 weeks
Change from baseline at week 12: age adjusted standard scores (higher score reflects positive outcome)
Time frame: 0 and 12 weeks
Change from baseline at week 12: microbiome composition
Time frame: 0 and 12 weeks
Change from baseline at week 12: plasma malondialdehyde (MDA)
Time frame: 0 and 12 weeks
Change from baseline at week 12: Gut inflammatory biomarkers fecal calprotectin and myeloperoxidase
Time frame: 0 and 12 weeks
Change from baseline at week 12: Plasma inflammatory markers (ex. CRP and IL-6)
Time frame: 0 and 12 weeks
Change from baseline at week 12: urolithin A and urolithin B concentrations in urine
Time frame: 0 and 12 weeks
Change from baseline at week 12: systolic and diastolic blood pressure
Time frame: 0 and 12 weeks
Change from baseline at week 12: weight
Contact information is provided by the study sponsor or research team.
Emily Ho, PhD
CONTACT
Sandra Uesugi, RN, BSN, MS
CONTACT
Oregon State University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07372417
Aging, Anesthesia Brain Monitor
Santiago, Santiago Metropolitan, Chile
View Trial DetailsNCT07414680
Aging, Behavior
Taipei, Taiwan
View Trial DetailsNCT07099053
Aging, Alzheimer Disease
Baltimore, Maryland, United States
View Trial DetailsNCT06269939
Aging
East Hanover, New Jersey, United States
View Trial Details